Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems

Investors have grown excited about Revolution Medicines due to its promising pancreatic cancer drug, daraxonrasib. Daraxonrasib significantly extended the life of patients in a recent clinical trial.